

## **CV Vasilios Gabriel ATHYROS, MD**

Dr. V.G. Athyros was born and raised in Thessaloniki Greece. He studied medicine and was trained in Internal Medicine in the Aristotle University of Thessaloniki, Greece.

He founded the Atherosclerosis and Metabolic Syndrome Outpatient Clinics in 1990 and he is the Head of these Clinics ever since until the present day. He has performed more than 330 studies, 292 entries in PubMed on lipoprotein metabolism, atherogenicity and clinical properties of plasma lipids and lipoproteins, in therapeutic interventions in all kinds of high risk patients including dyslipidemia, obesity, diabetes, arterial hypertension, and the metabolic syndrome, both in primary and secondary cardiovascular disease prevention. The Impact Factor of the publications is >1,200, the citations >9,500 and the H-Index is 47. He has also been a member of the Panel of European Experts who published a Consensus Document on the pathophysiology, atherogenicity and clinical significance of low density lipoprotein subclasses.

Dr. Athyros is a Faculty member at the School of Medicine, Aristotle University of Thessaloniki, Greece with a joint position in the Clinic of Internal Medicine at the University (Hippocraton) Hospital, Also, Dr. Athyros was a member of the Advisory board of the Hellenic Society of Lipidology since 1995 and from 2002 of the Hellenic (Greek) Atherosclerosis Society (HAS). He has been elected as Vice-President (2008-2010) and the as a President (2010-2012) of HAS, while he continues to be a member of the Advisory Board of HAS. From 2013 he is the Vice-President in the Hellenic (Greek) Society for Medical Education.

He has been the primary investigator in the prospective, randomized, controlled secondary prevention trial with statins GREACE (n=1,600, 3 years duration), the prospective, randomized, controlled primary prevention trial with statins ATTEMPT (n=1,200, 4 years duration), and the MetS GREECE epidemiological study (n=10,000) for metabolic syndrome and dyslipidaemia. He has participated in several national: IMPROVE, IMPULSION, IMPLICATE, and international multicenter interventional RCT: MIRACL, A-Z (Aggrastat to Zocor), ORLICARDIA, ECLIPSE, Actfast-2 FOURIER, and ODYSSEY ACS.

He is a member of IAS, EAS, ESC (fellow), ASA (fellow), RSPH (fellow), ASCS (fellow). He is Editor-in-Chief in the Open Hypertension Journal, Bentham (UK), Associate Editor in BMC Public Health Journal (UK), (Lipid) Section Editor in 3 Journals, and sits on the editorial board of 15 international journals.